Brian Low Financial Group LLC trimmed its position in shares of Astrazeneca Plc (NYSE:AZN – Free Report) by 45.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 9,162 shares of the company’s stock after selling 7,731 shares during the period. Astrazeneca accounts for about 1.2% of Brian Low Financial Group LLC’s investment portfolio, making the stock its 21st biggest holding. Brian Low Financial Group LLC’s holdings in Astrazeneca were worth $1,807,000 as of its most recent filing with the SEC.
Several other large investors have also recently modified their holdings of the company. IHT Wealth Management LLC lifted its position in Astrazeneca by 0.3% during the fourth quarter. IHT Wealth Management LLC now owns 17,527 shares of the company’s stock valued at $3,076,000 after acquiring an additional 54 shares during the last quarter. Visionary Wealth Advisors grew its holdings in Astrazeneca by 1.5% in the fourth quarter. Visionary Wealth Advisors now owns 4,197 shares of the company’s stock worth $737,000 after purchasing an additional 60 shares during the last quarter. Vista Investment Management increased its position in shares of Astrazeneca by 0.3% during the fourth quarter. Vista Investment Management now owns 21,215 shares of the company’s stock worth $3,723,000 after purchasing an additional 60 shares in the last quarter. Kestra Investment Management LLC increased its position in shares of Astrazeneca by 1.9% during the fourth quarter. Kestra Investment Management LLC now owns 3,391 shares of the company’s stock worth $595,000 after purchasing an additional 63 shares in the last quarter. Finally, Luken Investment Analytics LLC lifted its holdings in shares of Astrazeneca by 4.3% during the 4th quarter. Luken Investment Analytics LLC now owns 1,564 shares of the company’s stock valued at $274,000 after purchasing an additional 64 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.
Astrazeneca Stock Performance
Shares of AZN opened at $182.98 on Thursday. The stock has a 50-day moving average of $185.21 and a two-hundred day moving average of $186.69. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a market cap of $283.78 billion, a P/E ratio of 27.47, a P/E/G ratio of 1.57 and a beta of 0.25.
Wall Street Analysts Forecast Growth
A number of analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Astrazeneca in a research report on Wednesday, March 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 9th. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Barclays reissued a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Finally, Jefferies Financial Group restated a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $205.33.
Read Our Latest Report on Astrazeneca
Astrazeneca Company Profile
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
- Five stocks we like better than Astrazeneca
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca Plc (NYSE:AZN – Free Report).
Receive News & Ratings for Astrazeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca and related companies with MarketBeat.com's FREE daily email newsletter.
